The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBraveheart Inv Regulatory News (BRH)

Share Price Information for Braveheart Inv (BRH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.50
Bid: 7.00
Ask: 8.00
Change: 0.25 (3.45%)
Spread: 1.00 (14.286%)
Open: 7.25
High: 7.50
Low: 7.25
Prev. Close: 7.25
BRH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of General Meeting

18 Jun 2018 07:02

RNS Number : 6273R
Braveheart Investment Group plc
18 June 2018
 

18 June 2018

 

Braveheart Investment Group plc

("Braveheart", the "Company" or the "Group")

 

Notice of GM

Proposed Reduction of Share Capital

 

 

Braveheart Investment Group plc (AIM: BRH), the fund management and strategic investor group, announces that it proposes to carry out a capital reduction by cancelling the whole of its share premium account thereby enabling the Directors to consider the payment of dividends to its shareholders as a means of returning income to shareholders should the Directors consider it is appropriate to do so.

 

A General Meeting is being convened to be held on 19 July 2018 at 11.30 a.m. (or immediately following the conclusion or adjournment of the Annual General Meeting called at 11.00 a.m. on that date) at the offices of Edwin Coe, 2 Stone Buildings, Lincoln's Inn, London WC2A 3TH ("the General Meeting") in order to consider, and if thought fit, pass the resolution necessary to implement the proposal.

 

The Company's 2018 Annual Report and Accounts show its total liabilities as at 31 March 2018 as £1,434,382, and its retained earnings as at that date as £33,293. However, the retained earnings include unrealised profits of circa £270,000 and do not include contingent liabilities of £147,982. Consequently, the Company does not have any distributable profits and is unable to declare dividends.

 

At the same time, the Company's accounts show a sum of £1,567,615 standing to the credit of its share premium account. The share premium account is an undistributable reserve and, accordingly, the purposes for which a company can use the sums credited to this reserve are very limited. However, with the consent of its shareholders and the approval of the Court, a company may reduce or cancel its share premium account and the reserve arising on such a reduction of capital may be used in diminishing or extinguishing a deficit or maximising returns to shareholders.

 

The Company therefore proposes to cancel the whole of its share premium account in order to generate distributable reserves of approximately £1.295 million, which would enable the Company to pay dividends (should circumstances in the future make it desirable to do so) to the extent of the distributable reserves created but subject to the financial position of the Company and its prospects at the relevant time and any undertakings given to the Court for the protection of the Company's creditors at the date that the Capital reduction becomes effective.

 

The cancellation of the Company's share premium account will only take effect if sanctioned by the Shareholders at the General Meeting and confirmed by the Court and upon the appropriate documents being lodged with the Registrar of Companies.

 

An application to the Court will be made as soon as practicable after the passing of the required shareholder resolution and the procedure is expected to be completed within six to eight weeks following the passing of the required shareholder resolution.

 

The Directors have been advised that, having regard to the circumstances at the date of this document, the Court is expected to confirm the Capital Reduction. The Directors are not, however, able to guarantee the Court's confirmation of the Capital Reduction. It is important to note that the Capital Reduction will not take effect unless it is confirmed by the Court.

 

The Directors have also been advised that the Court may require that the Company give undertakings for the protection of the Company's creditors at the date that the Capital Reduction becomes effective.

 

As at 31 March 2018, the Company's liabilities (including contingent liabilities) amounted to a total of approximately £1,582,274, of which (i) £147,892 relates to contingent liabilities arising under the guarantees provided by the Company pursuant to section 479 of the Companies Act and (ii) the balance of £1,434,382 relates to debts owed by the Company. The majority of its creditors consist of subsidiaries of the Company, in respect of which there are debts of £1,371,373 and contingent liabilities of £105,841. The relevant subsidiaries of the Company have indicated that they will consent to the Capital Reduction to generate distributable reserves and agree not to seek repayment of the sums due to them until such time as the sums due to the balance of the creditors (the "Remaining Creditors") at the date on which the capital reduction takes effect (the "Effective Date") have been repaid in full. The Remaining Creditors at the Effective Date are due to be paid a total amount of approximately £63,000 and there are contingent liabilities to Remaining Creditors of approximately £42,000.

 

The Company will if required give an undertaking to the Court that the part of the distributable reserves created by the Capital Reduction equal to the sums due to the Remaining Creditors at the Effective Date will not be used for any other purposes without paying those Remaining Creditors the sums due to them on the Effective Date, except to the extent that the Remaining Creditors consent to those distributable reserves being used for other purposes.

 

A notice convening a General Meeting to consider and, if thought fit, pass the necessary resolution will be set out in a Circular which will be sent to shareholders shortly and will be available on the Company's website www.braveheartgroup.co.uk.

 

 

For further information:

 

Braveheart Investment Group plc +44 (0) 1738 587555

Trevor Brown, Chief Executive

 

Allenby Capital Limited (Nominated Adviser and Broker) +44 (0) 20 3328 5656

David Worlidge / Nicholas Chambers

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NOGBLGDLSUBBGIU
Date   Source Headline
29th Apr 20242:07 pmRNSHolding(s) in Company
29th Apr 20241:42 pmRNSBlock admission six monthly return
10th Apr 20247:00 amRNSHolding(s) in Company
27th Mar 202412:03 pmRNSHolding(s) in Company
6th Mar 20247:00 amRNSAcquisition of further interest in Autins Group
4th Mar 202411:48 amRNSInvestment update – Paraytec Limited
4th Mar 20247:00 amRNSCompletion of sale of Phasefocus
9th Jan 202412:00 pmRNSHolding(s) in Company
22nd Dec 20231:30 pmRNSHolding(s) in Company
22nd Dec 20237:00 amRNSPortfolio update - Proposed sale of Phasefocus
15th Dec 202311:41 amRNSInvestment update - Paraytec Limited
15th Dec 202310:16 amRNSReplacement: Half-year Report
14th Dec 20237:00 amRNSHalf-year Report
29th Nov 20237:00 amRNSInvestment update - Paraytec Limited
14th Nov 20239:02 amRNSHolding(s) in Company
17th Oct 20237:00 amRNSInvestment update – Paraytec Limited
10th Oct 202311:15 amRNSHolding(s) in Company
8th Sep 20237:00 amRNSInvestment update – Kirkstall Limited
8th Sep 20237:00 amRNSBlock admission six monthly return
21st Aug 20237:00 amRNSFurther investment in Phasefocus Holdings Limited
28th Jul 20232:25 pmRNSInvestment update on Paraytec Limited
28th Jul 202311:54 amRNSResult of AGM
5th Jul 20237:00 amRNSPosting of annual report and notice of AGM
4th Jul 20237:00 amRNSHolding(s) in Company
3rd Jul 20237:00 amRNSFinal Results for the year ended 31 March 2023
31st May 20237:00 amRNSInvestment update – Phasefocus Holdings Limited
3rd May 20237:00 amRNSUpdate on investments
24th Apr 202310:49 amRNSHolding(s) in Company
27th Mar 20237:00 amRNSGrant of options
13th Mar 20239:34 amRNSHolding(s) in Company
9th Mar 20237:00 amRNSBlock admission six monthly return
10th Feb 20231:26 pmRNSHolding(s) in Company
30th Jan 20234:37 pmRNSHolding(s) in Company
16th Jan 20237:00 amRNSDirector/PDMR Shareholding
10th Jan 20237:00 amRNSOperational update
22nd Dec 20229:14 amRNSHolding(s) in Company
19th Dec 20229:25 amRNSDirector/PDMR Shareholding
19th Dec 20229:11 amRNSAcquisition of interest in Image Scan Holdings plc
13th Dec 20224:37 pmRNSHolding(s) in Company
15th Nov 20223:09 pmRNSHolding(s) in Company
7th Nov 20227:00 amRNSDirector/PDMR Shareholding
28th Oct 20227:00 amRNSHalf-year Report
21st Oct 202210:33 amRNSHolding(s) in Company
20th Oct 20221:59 pmRNSAcquisition of further interest in Autins
5th Oct 20223:15 pmRNSHolding(s) in Company
5th Oct 202212:28 pmRNSAcquisition of further interest in Aukett Swanke
30th Sep 20225:00 pmRNSTotal Voting Rights
20th Sep 20227:00 amRNSPlacing and subscription to raise £750,000
9th Sep 20227:00 amRNSBlock admission six monthly return
6th Sep 20227:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.